康泰生物：重组乙型肝炎疫苗（酿酒酵母）（60μg）临床试验获批

Core Viewpoint - The company announced that its recombinant hepatitis B vaccine (yeast) (60μg) has received approval from the National Medical Products Administration for clinical trials aimed at preventing HBsAg reversion in patients with chronic hepatitis B who have achieved functional (clinical) cure [1] Group 1 - The vaccine is now approved for a new target population, specifically for individuals aged 16 to 64 who have clinically cured chronic hepatitis B [1] - The clinical trial will focus on preventing the reversion of HBsAg in this specific group [1]